Our data indicate that increased expression of NFκB regulators have an anti-myeloma effect, and this is supported by the high frequency of inactivating mutations found in these regulators (BIRC3, Traf2/3 and CYLD) in myeloma patients [48-51]. Here, TRAF2 is linked to plasma cell myeloma.